Biomarkers: Delivering on the expectation of molecularly driven, quantitative health
- PMID: 29199461
- PMCID: PMC5813871
- DOI: 10.1177/1535370217744775
Biomarkers: Delivering on the expectation of molecularly driven, quantitative health
Abstract
Biomarkers are the pillars of precision medicine and are delivering on expectations of molecular, quantitative health. These features have made clinical decisions more precise and personalized, but require a high bar for validation. Biomarkers have improved health outcomes in a few areas such as cancer, pharmacogenetics, and safety. Burgeoning big data research infrastructure, the internet of things, and increased patient participation will accelerate discovery in the many areas that have not yet realized the full potential of biomarkers for precision health. Here we review themes of biomarker discovery, current implementations of biomarkers for precision health, and future opportunities and challenges for biomarker discovery. Impact statement Precision medicine evolved because of the understanding that human disease is molecularly driven and is highly variable across patients. This understanding has made biomarkers, a diverse class of biological measurements, more relevant for disease diagnosis, monitoring, and selection of treatment strategy. Biomarkers' impact on precision medicine can be seen in cancer, pharmacogenomics, and safety. The successes in these cases suggest many more applications for biomarkers and a greater impact for precision medicine across the spectrum of human disease. The authors assess the status of biomarker-guided medical practice by analyzing themes for biomarker discovery, reviewing the impact of these markers in the clinic, and highlight future and ongoing challenges for biomarker discovery. This work is timely and relevant, as the molecular, quantitative approach of precision medicine is spreading to many disease indications.
Keywords: Biomarkers; drug discovery; mechanisms; molecular; precision medicine; therapeutics.
Similar articles
-
Cancer Biomarker Discovery for Precision Medicine: New Progress.Curr Med Chem. 2019;26(42):7655-7671. doi: 10.2174/0929867325666180718164712. Curr Med Chem. 2019. PMID: 30027846 Review.
-
Pharmacogenomics: Driving Personalized Medicine.Pharmacol Rev. 2023 Jul;75(4):789-814. doi: 10.1124/pharmrev.122.000810. Epub 2023 Mar 16. Pharmacol Rev. 2023. PMID: 36927888 Free PMC article. Review.
-
Leveraging big data to transform target selection and drug discovery.Clin Pharmacol Ther. 2016 Mar;99(3):285-97. doi: 10.1002/cpt.318. Clin Pharmacol Ther. 2016. PMID: 26659699 Free PMC article. Review.
-
Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.Am J Respir Crit Care Med. 2018 Dec 15;198(12):e116-e136. doi: 10.1164/rccm.201810-1895ST. Am J Respir Crit Care Med. 2018. PMID: 30640517 Free PMC article.
-
Integrative methods for analyzing big data in precision medicine.Proteomics. 2016 Mar;16(5):741-58. doi: 10.1002/pmic.201500396. Proteomics. 2016. PMID: 26677817 Review.
Cited by
-
Microbiota Implications in Endocrine-Related Diseases: From Development to Novel Therapeutic Approaches.Biomedicines. 2024 Jan 18;12(1):221. doi: 10.3390/biomedicines12010221. Biomedicines. 2024. PMID: 38255326 Free PMC article. Review.
-
A scientist engineer's contribution to therapeutic discovery and development.Exp Biol Med (Maywood). 2018 Oct;243(14):1125-1132. doi: 10.1177/1535370218813974. Epub 2018 Nov 20. Exp Biol Med (Maywood). 2018. PMID: 30458646 Free PMC article.
-
Translational Bioinformatics for Human Reproductive Biology Research: Examples, Opportunities and Challenges for a Future Reproductive Medicine.Int J Mol Sci. 2022 Dec 20;24(1):4. doi: 10.3390/ijms24010004. Int J Mol Sci. 2022. PMID: 36613446 Free PMC article. Review.
-
Meta-Analysis Reveals Both the Promises and the Challenges of Clinical Metabolomics.Cancers (Basel). 2022 Aug 18;14(16):3992. doi: 10.3390/cancers14163992. Cancers (Basel). 2022. PMID: 36010984 Free PMC article.
-
S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis.World J Gastroenterol. 2021 May 7;27(17):1973-1992. doi: 10.3748/wjg.v27.i17.1973. World J Gastroenterol. 2021. PMID: 34007134 Free PMC article.
References
-
- Collins DC, Sundar R, Lim JSJ, Yap TA. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics. Trends Pharmacol Sci 2017; 38:25–40 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources